Flecainide News and Research

RSS
Flecainide is a drug used to treat abnormal heart rhythms. It may also relieve neuropathic pain, the burning, stabbing, or stinging pain that may arise from damage to nerves caused by some types of cancer or cancer treatment.
Anti-arrhythmic agents linked to increased risk of falls

Anti-arrhythmic agents linked to increased risk of falls

Research opens possibility of developing single-dose gene therapy for inherited arrhythmias

Research opens possibility of developing single-dose gene therapy for inherited arrhythmias

ESC Guidelines recommend DNA analysis for post mortem assessment in young sudden death victims

ESC Guidelines recommend DNA analysis for post mortem assessment in young sudden death victims

ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI acquires approved ANDA for Flecainide Acetate tablets USP

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Flecainide, encainide drugs increase risk of sudden cardiac death

Flecainide, encainide drugs increase risk of sudden cardiac death

Short-term antiarrhythmic drug treatment postcardioversion could be effective

Short-term antiarrhythmic drug treatment postcardioversion could be effective

Antiarrhythmic short-term treatment useful for some patients

Antiarrhythmic short-term treatment useful for some patients

Study supports catheter ablation as first-line treatment for paroxysmal atrial fibrillation

Study supports catheter ablation as first-line treatment for paroxysmal atrial fibrillation

UC Davis computer model can test effects of anti-arrhythmia medications

UC Davis computer model can test effects of anti-arrhythmia medications

Strong link between leisure-time physical activity and AF among men

Strong link between leisure-time physical activity and AF among men

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

FDA grants approval for Abbott's antiretroviral medication Norvir

FDA grants approval for Abbott's antiretroviral medication Norvir

Ablation therapy better than drug therapy for heart rhythm disorder

Ablation therapy better than drug therapy for heart rhythm disorder